Educational Programs

NASH with Fibrosis: Updates from the Resmetirom Clinical Program
(as presented at AASLD 2021)

speaker_photo NASH with Fibrosis: Disease, MAESTRO program and Resmetirom MOA & Phase 2 Data UpdateManal Abdelmalek, MD, MPH

speaker_photo NASH with Fibrosis: AASLD UpdatesMazen Noureddin, MD

speaker_photo speaker_photo speaker_photo Q&A Rebecca Taub, MD
Manal Abdelmalek, MD, MPH
Mazen Noureddin, MD

BASL 2021 Scientific Communications

speaker_photo The contribution of metabolic co-morbidities and hepatic thyroid hormone dysregulation to the pathophysiology of NASHVlad Ratziu, MD, PhD

speaker_photo Madrigal Clinical Trial ProgrammeRebecca Taub, MD

speaker_photo Resmetirom Mechanism of ActionRebecca Taub, MD

Phase 3 Development of Resmetirom: a Liver-Directed Thyroid Hormone Receptor (THR)-Beta Agonist for the Treatment of Patients with NASH and Significant Liver FibrosisImpacting NASH: Focus on Liver and Cardiovascular Benefits
(as presented at EASL 2021)

speaker_photo The contribution of metabolic co-morbidities and hepatic thyroid hormone dysregulation to the pathophysiology of NASHVlad Ratziu, MD, PhD

speaker_photo The utilization of biomarkers for the identification of NASH patients and as predictors of treatment response in the clinical settingJörn Schattenberg, MD

speaker_photo Resmetirom as a treatment for NASH: Updates from the MAESTRO Phase 3 clinical trialsStephen A. Harrison, MD, FACP, FAASLD

speaker_photo speaker_photo speaker_photo Questions and Answers Stephen A. Harrison, MD, FACP, FAASLD
Vlad Ratziu, MD, PhD
Jörn Schattenberg, MD

Reduction in Fibrosis Steatohepatitis Imaging and Biomarkers in a 52-week Resmetirom NASH Trial
(as presented at EASL 2021)

speaker_photo Stephen A. Harrison
MD, FACP, FAASLD

MAESTRO Phase 3 NASH Clinical Trials of Resmetirom: Optimal Strategies for the Identification of NASH Patients with Significant Liver Fibrosis
(as presented at AACE 2021)

speaker_photo Stephen A. Harrison
MD, FACP, FAASLD

4th Global NASH Congress Scientific Communication

speaker_photo Rebecca Taub
MD

Madrigal: Advancing Resmetirom in Phase 3 Trials for non-cirrhotic NASH with Liver Fibrosis
(as presented at the 2021 Paris Hepatology Conference)

speaker_photo Rebecca Taub
MD

Patient Video Series in Partnership with the Fatty Liver Foundation (3 Parts)

speaker_photo Scott L. Friedman
MD

speaker_photo Wayne Eskridge

Part I -
Fatty Liver Foundation Development
Wayne Eskridge tells his personal journey as a patient with NASH and how it led him to develop the Fatty Liver Foundation.
Part II -
Advice for Patients with Recent Diagnosis of NASH with Fibrosis
Wayne Eskridge gives his advice to patients dealing with NASH, and NASH expert, Dr Scott Friedman, talks about what support clinicians should provide.
Part III -
After Diagnosis: What Happens Now?
Wayne Eskridge discusses what patients can do themselves to manage their disease, and Dr Scott Friedman talks about his outlook on future treatments for NASH.

Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials
(as presented at AASLD 2020)

speaker_photo Stephen A. Harrison
MD, FACP, FAASLD

Paris NASH 2020 Scientific Communication

speaker_photo Vlad Ratziu
MD, PhD

Impacting NASH: Focus on Liver and Cardiovascular Benefits
(as presented at EASL 2020)

speaker_photo Epidemiology of NASH—CV and Liver Related OutcomesZobair M. Younossi
MD, MPH, FACP, FACG, AGAF, FAASLD

speaker_photo Resmetirom for the Treatment of NASHStephen A. Harrison
MD, FACP, FAASLD

speaker_photo Real-life Treatment of NASH: Imaging in NASH. MRI-PDFF to Predict Benefit in Patients with NASH: Focus on ResmetiromRohit Loomba
MD, MHSc

speaker_photo The Intersection of CVD and NASH, the Next CVD Prevention FrontierSeth J. Baum
MD, FACC, FACPM, FAHA, FNLA, FASPC